Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy.

Translational oncology·2013
Same author

Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.

Cancer immunity·2013
Same author

Research on 2D representation method of wireless Micro-Ball endoscopic images.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2013
Same author

Photocatalytic properties of graphdiyne and graphene modified TiO₂: from theory to experiment.

ACS nano·2013
Same author

Relationship between the structures of flavonoids and oxygen radical absorbance capacity values: a quantum chemical analysis.

The journal of physical chemistry. A·2013
Same author

[Early diagnosis and treatment of acute mesentric ischemia for 42 cases in single center].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2013

Related Experiment Video

Updated: May 19, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.

Melissa Heffler1, Vita M Golubovskaya, Jeffrey Conroy

  • 1Department of Surgical Oncology, Roswell Park Cancer Institute and the University at Buffalo/State University of New York, Buffalo, NY 14263, USA.

Anti-Cancer Agents in Medicinal Chemistry
|September 1, 2012
PubMed
Summary

Dual inhibition of focal adhesion kinase (FAK) and hyaluronan synthase-3 (HAS3) synergistically reduces colon cancer cell viability. Targeting both FAK and HAS3 affects shared genes involved in tumor survival pathways, offering a promising therapeutic strategy.

More Related Videos

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Quantification of Cytokine-Induced Cell Death in Human Colonic Organoids Using Live Fluorescence Microscopy
10:03

Quantification of Cytokine-Induced Cell Death in Human Colonic Organoids Using Live Fluorescence Microscopy

Published on: August 2, 2024

Related Experiment Videos

Last Updated: May 19, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Quantification of Cytokine-Induced Cell Death in Human Colonic Organoids Using Live Fluorescence Microscopy
10:03

Quantification of Cytokine-Induced Cell Death in Human Colonic Organoids Using Live Fluorescence Microscopy

Published on: August 2, 2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Focal adhesion kinase (FAK), hyaluronan (HA), and hyaluronan synthase-3 (HAS3) are implicated in cancer progression.
  • FAK inhibition via Y15 reduces colon cancer cell growth.
  • HAS3 inhibition affects FAK activation, while HA enhances it.

Purpose of the Study:

  • To identify genes regulated by HAS and FAK inhibition.
  • To investigate the synergistic effect of dual FAK and HAS inhibition on colon cancer cell viability.
  • To explore the underlying genetic mechanisms of this synergistic effect.

Main Methods:

  • Treatment of colon cancer cells with FAK inhibitor (Y15) and HAS inhibitor (4-methylumbelliferone, 4-MU).
  • Dose-dependent viability assays to assess synergistic effects.
  • Microarray analysis to identify differentially expressed genes.

Main Results:

  • Combined Y15 and 4-MU treatment synergistically decreased colon cancer cell viability.
  • Microarray analysis revealed 121 genes affected by HAS inhibition and 696 by FAK inhibition.
  • 29 common genes were identified, involved in apoptosis, cell cycle, adhesion, and WNT pathways.

Conclusions:

  • Dual inhibition of FAK and HAS3 significantly reduces colon cancer cell viability more than single-agent treatment.
  • Targeting shared genetic pathways involved in tumor survival offers a potential therapeutic strategy.
  • This study highlights the synergistic potential of combined FAK and HAS3 inhibition in colon cancer treatment.